Roivant Sciences is trading at $36.20 (+4.91%) in pre-market action after fiscal Q4 2026 results significantly beat analyst expectations due to a major litigation-related windfall.
- The company reported EPS of $0.28 versus an anticipated $0.29 loss, with net income benefiting from a $770.2 million gain tied to its settlement with Moderna.
- Investors are reacting to a strengthened balance sheet featuring a $4.3 billion cash position and no debt, alongside pipeline catalysts such as the Priority Review for brepocitinib.